The total number of records retrieved from this search are 34. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_3314	Virus nameReovirus	Virus strainRecombinant reovirus T1L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationMutant in L1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration10 pfu	In-vitro result70% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3315	Virus nameReovirus	Virus strainRecombinant reovirus T1L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationMutant in L1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration100 pfu	In-vitro result50% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3316	Virus nameReovirus	Virus strainRecombinant reovirus T1L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationMutant in L1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration1000 pfu	In-vitro result30% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3317	Virus nameReovirus	Virus strainRecombinant reovirus T1L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationMutant in L1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration10 pfu	In-vitro result80% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3318	Virus nameReovirus	Virus strainRecombinant reovirus T1L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationMutant in L1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration100 pfu	In-vitro result30% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3319	Virus nameReovirus	Virus strainRecombinant reovirus T1L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationMutant in L1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration1000 pfu	In-vitro result10% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3320	Virus nameReovirus	Virus strainRecombinant reovirus T1L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationMutant in L1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration10 pfu	In-vitro result20% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3321	Virus nameReovirus	Virus strainRecombinant reovirus T1L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationMutant in L1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration100 pfu	In-vitro result5% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3322	Virus nameReovirus	Virus strainRecombinant reovirus T1L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationMutant in L1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration1000 pfu	In-vitro result100% cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3323	Virus nameReovirus	Virus strainRecombinant reovirus T3L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationSubstitution mutant in T3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration10 pfu	In-vitro result80% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3324	Virus nameReovirus	Virus strainRecombinant reovirus T3L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationSubstitution mutant in T3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration100 pfu	In-vitro result70% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3325	Virus nameReovirus	Virus strainRecombinant reovirus T3L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationSubstitution mutant in T3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration1000 pfu	In-vitro result70% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3326	Virus nameReovirus	Virus strainRecombinant reovirus T3L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationSubstitution mutant in T3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration10 pfu	In-vitro result100% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3327	Virus nameReovirus	Virus strainRecombinant reovirus T3L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationSubstitution mutant in T3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration100 pfu	In-vitro result80% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3328	Virus nameReovirus	Virus strainRecombinant reovirus T3L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationSubstitution mutant in T3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration1000 pfu	In-vitro result70% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3329	Virus nameReovirus	Virus strainRecombinant reovirus T3L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationSubstitution mutant in T3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration10 pfu	In-vitro result100% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3330	Virus nameReovirus	Virus strainRecombinant reovirus T3L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationSubstitution mutant in T3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration100 pfu	In-vitro result50% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3331	Virus nameReovirus	Virus strainRecombinant reovirus T3L	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationSubstitution mutant in T3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayCell-titer-glo assay	In-vitro virus concentration1000 pfu	In-vitro result50% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28587298
IDOV_3482	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration25 MOI	In-vitro result90% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3483	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration50 MOI	In-vitro result75% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3484	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 MOI	In-vitro result60% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3485	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (4 microgram/ml)	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 MOI	In-vitro result35% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3486	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration25 MOI	In-vitro result85% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3487	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration50 MOI	In-vitro result70% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3488	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 MOI	In-vitro result50% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3489	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (4 microgram/ml)	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 MOI	In-vitro result25% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3490	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration25 MOI	In-vitro result80% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3491	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration50 MOI	In-vitro result70% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3492	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 MOI	In-vitro result50% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3493	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (4 microgram/ml)	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 MOI	In-vitro result25% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3494	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration25 MOI	In-vitro result75% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3495	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration50 MOI	In-vitro result60% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3496	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 MOI	In-vitro result45% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3497	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (4 microgram/ml)	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH661	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 MOI	In-vitro result25% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457